Company Overview
Vision and Mission
Leadership Team
Board of Directors
ESG
The United Nations Global Compact
Contact Us
Pipeline and Major Products
Discovery
Manufacturing
Partners
Press Releases
Media Coverage
Awards
Presentations and Webcasts
Announcements and Circulars
Financial Reports and Listing Documents
Analyst Coverage
Corporate Governance
Events Calendar
IR Contact and Email Alert
Job Opportunities
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
Everest Medicines’ Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
Everest Medicines’ Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam’s Phase 3 CERTAIN-1 Study in New England Journal of Medicine
Everest Medicines Announces Termination of Collaboration Agreements with Providence
Everest Medicines Announces 2023 Revenue Expected to be Between RMB124 Million and RMB126 Million
Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients
Everest Medicines’ Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
Everest Medicines Announces Positive Topline Results from Induction Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderate-to-Severe Active Ulcerative Colitis
Everest Medicines Announces Acceptance of Nefecon® New Drug Applications for the Treatment of Primary IgA Nephropathy in Adult Patients in South Korea
Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon® Chinese Patient Data and to Hold Conference Calls
Everest Medicines’ Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
Everest Medicines’ Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023
Everest Medicines Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients
Everest Medicines Enters into Collaboration and License Agreement with Kezar Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and other Asian Markets
Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis
Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon® for the Treatment of Primary IgA Nephropathy
Everest Medicines Announces Interim Results for First Half of 2023